Esperion Reports Positive Results From Phase 2a Study Of ETC-1002

(RTTNews) - Clinical-stage biopharmaceutical company, Esperion Therapeutics, Inc. (ESPR), Tuesday reported positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy for patients with elevated levels of low density lipoprotein cholesterol. The study showed that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with zero percent in placebo.

Mayleben, president and chief executive officer of Esperion said, "This study answered important questions about the safety, tolerability and efficacy of ETC-1002 as an add-on to statin therapy."

The company said it plans a parallel-dose design Phase 2b study to establish further potential of ETC-1002 to provide incremental LDL-C lowering for patients on statin therapy.